ProKidney develops rilparencel, a cell therapy aimed at preserving kidney function in people with chronic kidney disease and diabetes. It last closed at $1.10 on Nov 17, up 5.77% on the day.
Only 1 firm rated PROK in the past 90 days, not enough for a consensus
Average 12-month target
$8.00
▲ 627.3% upside
Based on 1 analyst who set a price target on PROK in the past 90 days. The average target is $8.00, with a high of $8.00 and a low of $8.00, compared with the last close of $1.10.
Low $8.00Avg $8.00High $8.00
Blue marker: last close $1.10
Highest target$8.00
Average target$8.00
Lowest target$8.00
Latest rating changes
CitigroupMaintained
Oct 28Buy$8
HC Wainwright & Co.Reiterated
May 18Buy$12
Date
Firm
Action
Rating
Price target
Oct 28
Citigroup
Maintained
Buy
$8
May 18
HC Wainwright & Co.
Reiterated
Buy
$12
Loading…
Technical Analysis
PROK · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold
The stock is 12% below its 20 day and 36% below its 50 day average. It is 60% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 38), near oversold. The nearest support is the Pivot at $1.09, and the nearest resistance the Pivot R1 at $1.14.
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityHigh, 11.3%/day
Key levels
$2.6552 week high+140.9%
$1.76200 day average+60.0%
$1.59100 day average+44.5%
$1.4950 day average+35.5%
$1.27Swing high (Nov 9)+15.5%
$1.2420 day average+12.7%
$1.14Pivot R1+3.6%
$1.10Last close
$1.09Pivot−0.9%
$1.05Pivot S1−4.5%
$0.8752 week low−20.9%
$0.87Swing low (Nov 2)−20.9%
Indicators
RSI (14)
37.66
Weak, oversold below 30
Neutral
MACD
-0.12
Below its signal line
Bearish
Stochastic
27.4
Middle of its range
Neutral
ADX (14)
28.0
Trending down
Williams %R
-65.2
Oversold below −80, overbought above −20
Neutral
CCI (20)
-62.4
Oversold below −100, overbought above 100
Neutral
Rate of change
+2.8%
Change over 10 sessions
Bullish
ATR (14)
$0.12
Typical daily range, 11.3% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
Downtrend, nearing oversold
Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 26.5%/day
Key levels
$2.6552 week high+140.9%
$1.76200 day average+60.0%
$1.59100 day average+44.5%
$1.4950 day average+35.5%
$1.27Swing high (Nov 9)+15.5%
$1.2420 day average+12.7%
$1.14Pivot R1+3.6%
$1.10Last close
$1.09Pivot−0.9%
$1.05Pivot S1−4.5%
$0.8752 week low−20.9%
$0.87Swing low (Nov 2)−20.9%
Indicators
RSI (14)
37.91
Weak, oversold below 30
Neutral
MACD
-0.19
Below its signal line
Bearish
Stochastic
18.4
Near the bottom of its range
Oversold
ADX (14)
14.0
No clear trend
Williams %R
-81.2
Oversold below −80, overbought above −20
Oversold
CCI (20)
-161.2
Oversold below −100, overbought above 100
Oversold
Rate of change
−38.9%
Change over 10 sessions
Bearish
ATR (14)
$0.29
Typical daily range, 26.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for PROK
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how PROK did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow PROK usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PROK has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PROK is in one of them and how their past PROK trades turned out.
ProKidney is a biotechnology company developing rilparencel, a cell therapy meant to preserve kidney function in patients with chronic kidney disease and type 2 diabetes. The treatment is made from a patient's own kidney cells, which are collected from a small kidney biopsy, processed at the company's facility, and then injected back into the kidneys. The company is based in Winston-Salem, North Carolina, and its product is still in clinical development.